Rellevate

Digital banking platform enabling employers to offer their employees a benefit to get paid any day

Print
Follow Claim My Business
Security Type
Preferred Stock
Categories
Technology
Min Investment
$998
Location
STAMFORD, CT
Offering Date
February 10, 2022
Expected Close Date
April 30, 2022
Target Raise
$25.00K-$1.07M
Security Price
$3.04
Valuation
$13,500,000
Website
rellevate.com
Number of Employees
10
Cash
$1,058,063
Revenue
$101,224
Short Term Debt
$179,576
Cost of Goods
$146,070
Long Term Debt
$2,160,067
Net Income
$-619,103

Company Description

Rellevate is a B2B platform and our target market includes employers with hourly employees, across a range of industries. We have had success in acquiring employers in quick service retail, hospitality, schools, municipalities, and gig economy workforces. 

 

Perks

1. For any investors that open a Rellevate Digital Account: Receive Preferred Earnings Credit for the first 6 months.

2. Investments over $5,000 are eligible for a 1-hour virtual meet and greet with the Rellevate management team.

It is advised that you consult a tax professional to fully understand any potential tax implications of receiving investor perks before making an investment.

Please note that due to share price calculations, some final investment amounts may be rounded down to the nearest whole share - these will still qualify for the designated perk tier. Additionally, investors must complete the online process and receive an initial email confirmation by the deadline stated above in order to be eligible for perks.

Management Team / Advisory Board Bios

Chip Steppacher
Chief Financial Officer

Michele Sullender
Chief Marketing & Product Officer

Steven Sigman
Chief Operations Officer

Kim McCreven
Chief Revenue Officer
Amount Raised : $1,324,135
Reveal the Score by Voting
_
0
Business Idea
Business Traction
Management Team
Valuation

Security Description

Preferred securities are a type of investment that generally offers some sort of preferred treatment through a dividend or preferred treatment in a liquidation.

Research Reports

No reports have been submitted

Become a Reporter

0 Comments